| Literature DB >> 31877805 |
Angelika Jüptner1, Regina Scherließ1.
Abstract
Spray drying as a particle engineering technique is of increasing interest in the field of inhalation and is already being utilised e.g., for the PulmoSphereTM products. As spray dried particles tend to agglomerate and are mechanically instable, low dose filling processes can be difficult. This study correlates powder flowability tests of spray dried formulations with filling processes with drum and dosator systems. Four pulmonary and four nasal powders with different characteristics in terms of shape, composition, and surface polarity were prepared and characterised for powder flowability according to Ph. Eur. and by powder rheometry. All formulations were filled with a manual drum TT and a dosator system. The classical flowability tests according to the Ph. Eur. showed a bad flow behaviour for hydrophilic pulmonary powders (x50 ~ 3 µm), whereas hydrophobic pulmonary particles and nasal particles (x50 ~ 25 µm) showed a better flowing behaviour. Powder rheometry supports this finding but can better differentiate flow behaviours.Entities:
Keywords: FT4 powder rheometer; dosator; filling process; flowability tests; nasal application; pulmonary application; vacuum drum
Year: 2019 PMID: 31877805 PMCID: PMC7023205 DOI: 10.3390/pharmaceutics12010014
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Overview of composition of developed formulations for pulmonary and nasal application.
| P/S/phil | P/W/phil | P/S/phob | P/W/phob | N/S/phil | N/W/phil | N/S/phob | N/W/phob | |
|---|---|---|---|---|---|---|---|---|
| Solid content in spray dried solution ( | 2% | 2% | 2% | 2% | 10% | 10% | 10% | 10% |
| Concentration brilliant blue ( | 0.5% | 0.5% | 0.5% | 0.5% | 0.1% | 0.1% | 0.1% | 0.1% |
| Concentration mannitol ( | 99.5% | 98.5% | 89.5% | 69.5% | 99.9% | 98.9% | 89.9% | 81.9% |
| Concentration of added excipient ( | - | HPMC 4000 1% | Leucine 10% | Leucine 30% | - | HPMC 4000 1% | Leucine 10% | Leucine 18% |
Figure 1Picture of the used Drum TT equipment (Harro Höfliger).
Figure 2Picture of the used dosator system (Harro Höfliger).
Characterisation of pulmonary formulations (left) and nasal formulations (right). All values (except CA) are the mean of a threefold determination ± standard deviation. The CA values are the mean of a six-fold measurement ± standard deviation.
| Parameter | P/S/phil | P/W/phil | P/S/phob | P/W/phob | N/S/phil | N/W/phil | N/S/phob | N/W/phob |
|---|---|---|---|---|---|---|---|---|
| PSD in µm | 2.73 ± 0.02 | 2.92 ± 0.02 | 2.74 ± 0.03 | 2.66 ± 0.06 | 23 ± 0 | 26 ± 1 | 23 ± 0 | 27 ± 1 |
| Span | 1.86 | 1.86 | 1.91 | 2.08 | 1.01 | 1.93 | 2.44 | 1.69 |
| CA in ° | 26 ± 4 | 33 ± 3 | 67 ± 9 | 85 ± 3 | 28 ± 4 | 25 ± 2 | 69 ± 4 | 81 ± 5 |
| SSA in m2/g | 1.88 ± 0.02 | 2.18 ± 0.04 | 1.55 ± 0.11 | 3.28 ± 0.07 | 0.38 ± 0.03 | 0.86 ± 0.04 | 0.96 ± 0.08 | 0.95 ± 0.04 |
| BD in g/mL | 0.23 ± 0.00 | 0.27 ± 0.00 | 0.36 ± 0.00 | 0.26 ± 0.00 | 0.36 ± 0.01 | 0.49 ± 0.01 | 0.47 ± 0.01 | 0.24 ± 0.00 |
| TD in g/mL | 0.33 ± 0.01 | 0.39 ± 0.00 | 0.56 ± 0.00 | 0.44 ± 0.02 | 0.48 ± 0.01 | 0.60 ± 0.00 | 0.66 ± 0.00 | 0.37 ± 0.01 |
| HR | 1.45 ± 0.02 | 1.43 ± 0.02 | 1.54 ± 0.01 | 1.70 ± 0.07 | 1.32 ± 0.03 | 1.23 ± 0.01 | 1.39 ± 0.03 | 1.56 ± 0.05 |
| CI in % | 31 ± 1 | 30 ± 1 | 35 ± 1 | 41 ± 2 | 24 ± 2 | 18 ± 0 | 28 ± 1 | 36 ± 2 |
| Classification of flow according to Ph. Eur. | Poor | Poor | Very poor | Extremely poor | Slightly poor | Fair | Poor | Very poor |
| AoR in ° | 37 ± 3 | 46 ± 1 | 41 ± 2 | 40 ± 2 | 36 ± 1 | 31 ± 3 | 20 ± 3 | 34 ± 3 |
| Fto in s/100 g | 37 ± 5 | 148 ± 45 | 1 ± 1 | 2 ± 0 | 4 ± 3 | 1 ± 0 | 1 ± 0 | 2 ± 0 |
Figure 3Scanning electron microscopy (SEM) images of pulmonary formulations in the top row. SEM images of the nasal formulations in the bottom row. Magnification of 5000× used for pulmonary formulations and magnification of 500× used for nasal formulations.
Characterisation of pulmonary and nasal formulations with FT4 Powder Rheometer. All values are mean values of a threefold determination ± standard deviation.
| Parameter | P/S/phil | P/W/phil | P/S/phob | P/W/phob | N/S/phil | N/W/phil | N/S/phob | N/W/phob |
|---|---|---|---|---|---|---|---|---|
| SI | 1.30 ± 0.04 | 1.35 ± 0.14 | 2.71 ± 0.24 | 4.60 ± 0.58 | 1.31 ± 0.08 | 1.14 ± 0.11 | 1.28 ± 0.05 | 1.37 ± 0.22 |
| BFE in mJ | 38.7 ± 3.72 | 23.6 ± 1.85 | 14.93 ± 0.21 | 19.50 ± 2.35 | 31.6 ± 1.21 | 54.1 ± 0.65 | 22.89 ± 0.64 | 15.55 ± 0.77 |
| FRI | 2.46 ± 0.41 | 3.31 ± 0.71 | 4.87 ± 0.21 | 3.82 ± 0.19 | 2.37 ± 0.06 | 1.63 ± 0.01 | 2.21 ± 0.12 | 2.28 ± 0.14 |
| SE in mJ | 4.85 ± 0.67 | 5.11 ± 1.59 | 3.51 ± 0.57 | 3.56 ± 0.19 | 3.19 ± 0.19 | 3.23 ± 0.11 | 1.80 ± 0.03 | 2.10 ± 0.05 |
| ffc | 3.30 ± 0.6 | 1.99 ± 0.16 | 5.27 ± 0.46 | 4.15 ± 0.03 | 7.4 ± 0.1 | 8.8 ± 1.4 | 22.5 ± 3.4 | 14.7 ± 0.3 |
| Compress (15 kPa) in % | 48 ± 2 | 41 ± 1 | 47 ± 6 | 42 ± 2 | 22 ± 1 | 18 ± 0 | 16 ± 0 | 33 ± 1 |
Figure 4SEM images of N/S/phil (left) and N/W/phob (right). Magnification of 2500× was used. A difference in wall thickness can be seen.
Fill weights with standard deviation and relative standard deviation (RSD) of n = 20 dosing procedures for the dosator and drum system. n.a. = not available, if the filling could not be conducted.
| P/S/phil | P/W/phil | P/S/phob | P/W/phob | N/S/phil | N/W/phil | N/S/phob | N/W/phob | |
|---|---|---|---|---|---|---|---|---|
| Fill weight in mg | 6.10 ± 0.36 | 7.78 ± 0.38 | 11.92 ± 0.08 | 9.57 ± 0.18 | 17.37 ± 0.10 | 18.50 ± 0.17 | 19.37 ± 0.08 | 13.49 ± 0.12 |
| RSD in % | 5.84 | 4.85 | 0.66 | 1.89 | 0.58 | 0.95 | 0.41 | 0.91 |
| Fill weight in mg | 9.89 ± 0.5 | 9.81 ± 0.66 | n.a. | n.a. | 16.12 ± 0.67 | 24.36 ± 1.16 | 20.40 ± 0.81 | 7.27 ± 1.15 |
| RSD in % | 5.03 | 6.70 | n.a. | n.a. | 4.16 | 4.77 | 3.98 | 15.77 |
Figure 5Correlation of RSD of filling trials with drum system and ffc as flowability measure. Blue dotted line represents the regression line for pulmonary and the grey dotted line the regression line for nasal formulations (n = 20).